Practical experience with dapagliflozin: case reports

Czech version

Authors: Viliam Vaník ¹; Zbynek Schroner ²
Authors‘ workplace: Diabetologická ambulancia, Nemocnica Svet zdravia, Svidník ¹; Lekárska fakulta, Univerzita Pavla Jozefa Šafárika v Košiciach ²
Published in: Diab Obez 2023; 23(45): 37-42
Category:

Overview

In addition to glycemic control, the main goal of comprehensive treatment of type 2 diabetes mellitus is to reduce overall cardiovascular and renal risk. The cardioprotective and renoprotective effect of SGLT2 inhibitors (SGLT2i) has been confirmed in recently completed clinical trials even in non-diabetic patients. Two case reports from routine clinical practice in the Slovak Republic discuss the effect of one of the SGLT2i – dapagliflozin in a patient with type 2 diabetes mellitus (DM2T) and concomitant chronic kidney disease, and also in a patient with DM2T without cardiovascular disease but with cardiovascular risk factors already present. Both case reports demonstrate that the effect of treatment with this group of pharmaceuticals is very pronounced and, above all, early.

Keywords:

type 2 diabetes mellitus – chronic kidney disease – SGLT2 inhibitor – dapagliflosin

Sources

1. McMurray JJ, Solomon SD, Inzucchi SE et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381(21): 1995–2008. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1911303>.

2. Heerspink HJ, Stefánsson BV, Correa-Rotter R et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383(15): 1436–1446. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2024816>.

3. Solomon SD, de Boer RA, DeMets D et al. Eur J Heart Fail 2021; 23(7): 1217–1225. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.2249>.

4. Anker SD, Butler J, Filippatos G et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385(16): 1451–1461. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2107038>.

5. Herrington WG, Natalie Staplin N, Wanner C et al. [EMPA-KIDNEY Collaborative Group]. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023; 388(2): 117–127. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2204233>.

6. Packer M, Anker AD, Butler J et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383(15): 1413–1424. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2022190>.

7. Forxiga. Súhrn charakteristických vlastností lieku. Dostupné z WWW: <https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_sk.pdf>.

8. Schroner Z, Uličiansky V. SGLT2 inhibítory ako druhá voľba po zlyhaní metformínu. Súč Klin Prax 2015; 1: 24–27.

9. Davies MJ, Aroda VR, Collins BS et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022; 45(11): 2753–2786. Dostupné z DOI: <https://doi.org/10.2337/dci22–0034>.